Loading stock data…
OKUR
$4.29+0.03 (+0.82%)
Market OpenUpdated 1:31 PM EDT
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OnKure Therapeutics, Inc. in the Healthcare sector is trading at $4.29. Wall Street consensus targets $20.20 (5 analysts), implying a +371.4% move over the next 12 months. The stock is currently 20% below its 52-week high of $5.38, remaining 30.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +371.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.62M↓ | -$14.13M↑ | -$15.50M↑ | -$16.32M↑ | -$17.00M |
| Net Income | -$15.16M↓ | -$13.50M↑ | -$14.70M↑ | -$15.39M↑ | -$15.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-2...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.87%
Volume
Today's trading volume
88,609
Recent News
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.
Promising Penny Stocks To Watch In December 2025
As the Federal Reserve's meeting unfolds, investors are closely monitoring potential interest rate cuts that could influence market dynamics. Amid these developments, penny stocks continue to capture attention as a viable investment area, despite their seemingly outdated label. These smaller or newer companies can offer unique opportunities for growth and value, especially when they demonstrate strong financial resilience.
3 Promising Penny Stocks With Market Caps Under $200M
As the U.S. stock market shows signs of resilience with major indices like the Nasdaq and S&P 500 posting gains, investors are increasingly looking for opportunities beyond the usual tech giants. Penny stocks, a term that might seem outdated, still represent a compelling investment area by offering access to smaller or newer companies at lower price points. When these stocks are supported by strong financials and solid fundamentals, they can provide potential growth opportunities without many...
Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky
NasdaqGM:OKUR 1 Year Share Price vs Fair Value Explore OnKure Therapeutics's Fair Values from the Community and select...